In HNSCC, miR-34a is frequently reduced; restoring miR-34a activity not only targets oncogenic MET but also associates with an antitumor immune milieu (higher Th1 and naïve CD8+ T-cell frequencies) and fewer PD-L1+ tumor-associated macrophages [31]. The gene discussed is CD8A; the disease is neoplasm.